Accession Number:

AD1094491

Title:

POLD4 Gene Expression as a Prognostic Indicator for Synthetic Lethality with PARP Inhibitors in Lung Cancer Cells

Descriptive Note:

Technical Report,01 Aug 2018,31 Jul 2019

Corporate Author:

New York Medical College Valhalla United States

Personal Author(s):

Report Date:

2019-11-01

Pagination or Media Count:

10.0

Abstract:

The major goals of this project were to generate p12 knockout cell lines and use these, as well as the wild-type cell lines, to demonstrate that loss of p12 leads to heightened sensitivity to chemotherapeutic agents and PARP inhibitors. In parallel, the sensitivities of small cell lung cancer cell SCLC lines that lack p12 would be studied. The goals of the study were to generate p12 knockout cells, and to analyze their sensitivities to the PARP inhibitors, The results showed that depletion of p12 in cultured cells leads to a defect in homologous recombination, and also increased sensitivity to the PARP inhibitors Olaparib, Niraparib, Rucaparib and Talazoparib. SCLC cells exhibit high sensitivity to PARP inhibitors, equal or greater than that of the p12 knockout cells. The significance of these findings is that they identify p12 expression as being required for homologous recombination. The findings also provide a basis for the prediction that cancers low in p12 expression should exhibit enhanced sensitivity to PARP inhibitors. The findings also provide a greater understanding of the specific roles of the two forms of DNA polymerase delta in human cells. The p12 is a subunit of the heteroetrameric Pol delta4 form, but is absent in the trimeric Pol delta3 form. Our studies support the concept that Pol delta3 is required for cellular DNA replication, while Pol delta4 is dispensible but is required for homologous recombination.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE